Duchenne therapy may be evolving from slowing disease to reversing it—with RNA approaches offering the prospect of restoring function.

MISSISSAUGA, ON, Oct. 2, 2025 /CNW/ - Kye Pharmaceuticals ("Kye") announced today that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne Muscular Dystrophy (DMD) in boys a ...

Panelists discuss how recent advancements in muscular dystrophy treatment have evolved toward truly disease-modifying therapies using gene replacement, antisense oligonucleotides, and gene transfer ...

Every movement we make, whether walking, speaking or even breathing, depends on the health of our muscles and nerves. For people living with one of the more than 300 rare conditions known as ...

Pathologic changes of the X-chromosome gene for dystrophin give rise to Duchenne muscular dystrophy (DMD), and dystrophin -- which minimizes muscle fiber loss due to sarcolemma contraction damage when ...